Q4 FY26 saw revenue of $3.6m, ARR of $14.4m, and a cash balance of $15.3m, supported by a capital raise. SOZO unit sales grew in the U.S., reimbursement coverage reached 95%, and the company is targeting cost reductions and expansion in key healthcare segments.Original document: Impedimed Limited…
Q4 FY26 saw revenue of $3.6m, ARR of $14.4m, and a cash balance of $15.3m, supported by a capital raise. SOZO unit sales grew in the U.S., reimbursement coverage reached 95%, and the company is targeting cost reductions and expansion in key healthcare segments.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
